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The  Mas  protooncogene  encodes  a G  protein-coupled  receptor  that  has  been  described  as  a  functional
receptor  for  the  cardioprotective  fragment  of  the  renin-angiotensin  system  (RAS),  Angiotensin  (Ang)-
(1-7).  The  aim  of this  current  study  was  to  evaluate  the  responsiveness  of  Mas  expression  in  hearts
during  different  physiological  and  pathological  conditions  in  rats.  Physical  training  was  considered  a
physiological  condition,  while  isoproterenol-induced  hypertrophy,  myocardial  infarction  and  DOCA-salt
model  of hypertension  were  used  as pathological  models  of heart  injury.  The  expression  of  Mas  was
analyzed  by western  blotting.  Although  swim-trained  rats  presented  signiﬁcant  cardiac  hypertrophy,
our  physical  training  protocol  was  unable  to induce  changes  in  the  expression  of Mas.  On  the othersoproterenol treatment
yocardial infarction
OCA-salt rats
hand,  cardiac  hypertrophy  and  damage  elicited  by isoproterenol  treatment  led  to  a reduction  in Mas
expression.  Myocardial  infarction  also  signiﬁcantly  decreased  the  expression  of  Mas  after  21 days  of
myocardial  ischemia.  Additionally,  Mas  expression  levels  were  increased  in  hearts  of DOCA-salt  rats.
Our  present  data  indicate  that  Mas  expression  is  responsive  to  different  pathological  stimuli,  thereby
suggesting  that  Mas  receptor  is  involved  in the  homeostasis  of  the  heart,  as  well  as  in the  establishment
and  progression  of  cardiac  diseases.. Introduction
It has become apparent that the biologically active member of
he renin-angiotensin system (RAS), the heptapeptide Angiotensin
Ang)-(1-7), holds cardioprotective actions [4,5,18,23]. This peptide
s formed through the degradation of Ang II by the angiotensin-
onverting enzyme (ACE) homolog, ACE2, yet other enzymes
uch as the metallopeptidase neprilysin are also able to produce
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Ang-(1-7) directly from Ang I [23]. However, recent reports have
indicated that ACE2 is the principal enzyme and pathway involved
in the Ang-(1-7) generation in key organs as heart and kidney
[11,26]. Under physiological and pathological states, it is now rec-
ognized that Ang-(1-7) opposes many cardiac actions of Ang II by
binding to the Mas  receptor [22], and triggering signaling path-
ways leading to vasodilation, anti-ﬁbrotic, anti-hypertrophic and
anti-arrhythmic actions [5,8,23].
Functionally, the conﬁrmation that Mas  is a receptor for Ang-(1-
7) came from mice which present genetic deletion of this receptor
(Mas knockout mice). For example, the vasodilator effect of Ang-
(1-7) is absent in these mice [13]. Moreover, Mas  knockout mice
showed pronounced impairment of the cardiac [3,24] and renal
functions [16] and Mas  deﬁciency leads to dramatic changes in glu-
cose and lipid metabolisms, inducing a metabolic syndrome-like
state [25].
Open access under the Elsevier OA license.It is known that the expression and/or activity of the major
enzymes, peptides and receptors of the RAS change according to
different pathophysiological conditions of the heart. Furthermore,
these changes depend on the stage of the disease. For example,
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shiyama et al. [10] found a reduction in AT1 expression in the
hronic phase of the myocardial infarction (MI)-induced cardiac
emodeling (28 days). Importantly, these alterations occurred
ithout modiﬁcations of cardiac ACE and ACE2 mRNA levels. In
ddition, Ocaranza et al. [15] observed an increase in cardiac ACE2
ctivity after 1 week of MI  followed by a reduction in its activity
fter 8 weeks of the injury. Reduced cardiac expression of AT2 was
lso observed in the early post injury period in infarcted hearts, but
ot at the later failure stage [12]. Previous studies have also inves-
igated the levels of Ang II and Ang-(1-7) in the injured heart. While
hang et al. [27] reported an increase in Ang I and Ang II immunore-
ctivity in the heart of adult rats after 7 days of coronary artery
arrowing, Santiago et al. [21] found no signiﬁcant differences in
ng-(1-7) levels in the left ventricles of DOCA-salt hypertensive
ats when compared to their controls. Together, these studies sup-
ort the notion that expression levels of members of the RAS are
egulated independently in order to maintain cardiac homeostasis.
In addition to ACE2 and Ang-(1-7), Mas  is part of the cardio-
rotective axis of the RAS, therefore it is of major importance to
etermine whether cardiac Mas  expression is modulated at distinct
hysiological and pathological conditions. In our recent report, we
ave submitted Wistar rats and spontaneously hypertensive rats
SHRs) to a physical training protocol. Interestingly, only SHR pre-
ented an increase in left ventricular Mas  expression in response
o exercise training [9],  indicating that cardiac Mas  expression
an be regulated not only according to the stimulus, physiologi-
al or pathological, but also according to the state of the animal,
.e. healthy or diseased. Therefore, the aim of this study was to
valuate the responsiveness of Mas  expression in rat hearts sub-
itted to pathological challenges such as myocardial hypertrophy,
nfarction and hypertension, and under a physiological condition
physical exercise training).
. Materials and methods
.1. Animals
Three month-old male Wistar and Sprague-Dawley (SD) rats
ere used in this study. The animals were provided by the animal
acility of the Biological Sciences Institute (CEBIO, Federal Uni-
ersity of Minas Gerais) and housed in a temperature (22–24 ◦C)
nd humidity-controlled room maintained on a 12:12-h light–dark
chedule with free access to food and water. All animal procedures
ere performed in accordance with guidelines for the humane use
f laboratory animals at our Institute and were approved by local
uthorities.
.2. Physical training
The exercise training was performed in swimming pools with
ontrolled temperature (31 ± 1 ◦C) for 40–60 min  per day, 5 days
er week over 10 weeks. After the ﬁrst week of adaptation in the
wimming pools, Wistar rats (3 month-old, n = 4–6) were submit-
ed to a progressive load test, which consisted of an increasing
orkload corresponding to 2% of body weight added every 3 min
ntil exhaustion. This test was repeated at the end of the physical
raining protocol. Exercise intensity of the endurance training was
et at 50–80% (second and third weeks: 40–60 min  at 50%; fourth
eek: 40 min  at 60%; ﬁfth week: 40 min  at 70%; and sixth to tenth
eeks: 40–60 min  at 80%) of the maximal weight obtained in the
rogressive test. The maximal weight carried by the animal in the
rogressive load test was converted to percentage of the animal
ody weight. Thus, every week the rats were weighed, and using the
reviously calculated percentage value, a new maximal load was
btained and the 50–80% workload was determined. With this pro-
edure, we eliminated the need for performing the progressive loaddes 35 (2012) 196–201 197
test on a weekly basis [1].  At the end of the training, the rats were
killed by decapitation and the hearts were immediately removed.
Left ventricular wet  weights were recorded, normalized for body
weight and then expressed as cardiac mass index (mg/g). The left
ventricles were used for histology and western blot analysis.
2.3. Isoproterenol treatment
Wistar rats (n = 4) were daily (7 days) treated with either
isoproterenol (2 mg/kg, Sigma–Aldrich) or vehicle (0.9% NaCl,
0.1 ml/100 g, s.c.; control group). At the end of the 7-day period, the
rats were killed by decapitation and the hearts were immediately
removed. Wet  weights of left ventricles were recorded, normal-
ized for body weight and then expressed as cardiac mass index
(mg/g). The left ventricles were used for histology and western blot
analysis.
2.4. DOCA-salt model of hypertension
SD rats (n = 8–10) were nephrectomized (left kidney) under
tribromethanol (0.25 g/kg, i.p.) anesthesia. Part of the animals
(DOCA) were implanted with a subcutaneous pellet (Silicone rub-
ber encapsulant, Down-Corning) containing deoxycorticosterone
acetate (DOCA; 200 mg/kg; Sigma) and had a solution of 0.9% NaCl
and 0.2% KCl to drink for 6 weeks, as previously described [21]. Con-
trol rats were only uninephrectomized. Systolic arterial pressure
(SAP) was evaluated by tail-cuff plethysmography (RTBP2000, Kent
Scientiﬁc) 1 day before and each 7 days of treatment during 6 weeks.
Rats were submitted to echocardiographic evaluation, as previously
described [14]. Left ventricular wet weights were recorded, nor-
malized for tibial length and then expressed as cardiac mass index
(g/cm). In addition, left ventricles were also used for western blot
analysis.
2.5. Myocardial infarction
Under anesthesia with 10% ketamine/2% xylazine (4:3,
0.1 ml/100 g, i.p.), Wistar rats (n = 3–5) were placed in the supine
position on a surgical table, tracheotomized, intubated and venti-
lated with room air using a respirator for small rodents. The chest
was opened by a left thoracotomy at the fourth or ﬁfth intercostal
space. To expose the heart, a small-sized retractor was  used to
maintain the ribs separated. After incision of the pericardium, the
heart was  quickly removed from the thoracic cavity and turned
left to allow access to the proximal left anterior descending (LAD)
coronary artery. A 4-0 silk suture was snared around the LAD and
tightly ligated to occlude the vessel. The heart was then placed back
and the chest was  closed with 4-0 silk sutures. Sham-operated rats
were treated in the same manner, but the coronary artery was not
ligated. At 7 and 21 days after MI,  left ventricular samples were
used for western blot analysis.
2.6. Histological analysis
Before the sacriﬁce, the animals were injected with 30 mM KCl
to cause cardiac arrest in diastole. Left ventricular samples were
kept in 4% Bouin ﬁxative for 24 h at room temperature, dehydrated
and imbedded in parafﬁn. Transversal sections (6 m) were cut at
intervals of 40 m and stained with Masson’s trichrome to con-
ﬁrm the presence of infarct or with hematoxylin and eosin for cell
morphometry, as previously described [6,14].2.7. Western blot analysis
Left ventricular samples were homogenized in lysis buffer con-
taining 50 mM sodium pyrophosphate, 50 mM NaF, 50 mM NaCl,
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Fig. 1. Mas  expression in ventricular myocytes. (A) Mas  expression levels in ventric-
ular myocytes from 3 month-old Wistar rats. Testicular sample was used as positive
control in the western blot assay. (B) The top panel shows confocal immunoﬂuores-98 M.F. Dias-Peixoto et al. 
 mM EDTA, 5 mM  EGTA, 2 mM Na3VO4, 10 mM HEPES pH 7.4, 0.5%
riton 100, 1 mM PMSF, 1 g/ml leupeptin and 1 g/ml aprotinin.
rotein concentration of each sample was determined and samples
ontaining 30 g of protein were run on a 10% SDS-PAGE gel and
ransferred onto a nitrocellulose membrane. Following 1 h blocking
ith 5% nonfat dry milk in phosphate buffered saline (PBS) con-
aining 0.2% Tween 20 (PBS-T), the membrane was probed with
ntibody against Mas  (1:1000) [2,20] during 2 h at room tempera-
ure. The membranes were washed 4 times for 15 min  in PBS-T and
ncubated with anti-mouse IgG-HRP-conjugated secondary anti-
ody (1:2000) for 1 h. Afterward, the membranes were washed 4
imes for 15 min  in PBS-T, incubated with chemiluminescent agent
ECL plus, Amersham Biotechnology) for 1 min  and exposed to a
lm to visualize protein bands. Glyceraldehyde 3-phosphate dehy-
rogenase (GAPDH; 1:5000, Santa Cruz Biotechnology) bands were
nalyzed in parallel and used as a loading control for normaliza-
ion of the Mas  protein levels using the software ImageQuantTM.
as  polyclonal antibody was produced in Mas  knockout mice using
s antigen a 12 amino acid peptide (LAEEKAMNTSSR) correspond-
ng to the NH2-terminal domain of the mouse Mas  protein. This
equence has 100% homology with mouse and 91.6% homology
ith rat Mas  and it is not present in any other known protein
see Fasta protein database, www.ebi.ac.uk/fasta33). To conﬁrm
ur ﬁndings we repeated some immunoblotting experiments with
 commercial anti-Mas antibody (1:1000, Alomone).
.8. Immunoﬂuorescence
Cardiomyocytes were ﬁxed in 2% paraformaldehyde solution
iluted in PBS for 15 min. For immunostaining, cells were incubated
ith 5% bovine serum albumin (BSA) in PBS containing 5 mg/ml of
aponin for 1 h followed by incubation with a polyclonal antibody
gainst Mas  raised in Mas  deﬁcient mice and diluted at 1:25 [2,20].
n order to conﬁrm that the entry of the antibody into the cell was
chieved, cardiac cells were probed with an antibody against the
ntracellular Ca2+ channel, the type 2 ryanodine receptor (RyR2)
diluted 1:50, Afﬁnity BioReagents) overnight at 4 ◦C. Afterward,
hey were incubated with goat anti-mouse IgG conjugated with
lexa 633 for 1 h at room temperature. Each step was followed by
ashing the cells with PBS. The cells were mounted and viewed
ith a laser scanning confocal microscope (Zeiss 510 Meta-CEMEL
CB, UFMG). All confocal settings (aperture, gain and laser power)
ere determined at the beginning of the imaging session and these
arameters were not changed.
.9. Statistical analysis
All data are expressed as mean ± SEM. Statistical signiﬁcance
as estimated using Student t-test (GraphPad Prism 4.0). The level
f signiﬁcance was set at p < 0.05.
. Results
.1. Mas  expression in the heart
To evaluate the expression and localization of Mas  in isolated
entricular myocytes from adult rats, we used western blotting
nd immunoﬂuorescence-labeling techniques. As expected, it was
bserved that Mas  is expressed in ventricular myocytes (Fig. 1A).
esticular samples were used as positive controls. Furthermore,
his receptor was mainly localized in the sarcolemma of cardiomy-
cytes and absent in T-tubules (Fig. 1B). In order to assess the
fﬁciency of our permeabilization protocol, immunoﬂuorescence
as performed using an antibody against RyR2, an intracellular
a2+ channel located in the sarcoplasmic reticulum (Fig. 1B).cence image of Mas  localization in the sarcolemma of ventricular cardiomyocytes.
Bottom panel shows ryanodine receptor localization in the sarcoplasmic reticulum
of  ventricular myocytes.
3.2. Effects of exercise training on Mas expression in hearts
Physical training was  used as a physiological stimulus. Rats sub-
jected to swim training for 1 h 5 days a week during 10 weeks
developed signiﬁcant cardiac hypertrophy as demonstrated by
the cardiac mass index (3.41 ± 0.02 mg/g in untrained rats vs.
3.84 ± 0.10 mg/g in trained rats, Fig. 2A) and by the measurement
of cardiomyocyte diameter (10.25 ± 0.55 m in untrained animals
vs. 12.50 ± 0.01 m in trained rats, Fig. 2B). The efﬁciency of our
physical training protocol was further conﬁrmed by the increased
time to reach exhaustion at the progressive load test observed in
trained rats when compared with untrained group (approximately
87% increase in the trained group, data not shown). In spite of this
change in performance, no signiﬁcant difference in Mas protein
levels was  observed between left ventricles from sedentary and
swim-trained rats (Fig. 2C and D).
3.3. Effects of isoproterenol treatment on Mas expression in hearts
Cardiac hypertrophy and damage induced by isoproterenol,
myocardial infarction and DOCA-salt hypertension were employed
to evaluate the response of Mas  expression to distinct pathological
conditions. Isoproterenol treatment elicited a marked increase in
cardiac mass index (3.55 ± 0.17 mg/g in control vs. 4.40 ± 0.10 mg/g
in isoproterenol-treated rats, Fig. 3A). This result was conﬁrmed by
the measurement of cardiomyocyte diameter (9.95 ± 0.23 m in
control vs. 12.27 ± 2.12 m in isoproterenol-treated rats, Fig. 3B).
Interestingly, this effect was accompanied by a reduction in Mas
expression in left ventricles (Fig. 3C and D).
3.4. Effects of DOCA treatment on cardiac Mas  expression
Next, we  used the DOCA-salt model of hypertension to inves-
tigate changes in Mas  expression. Three weeks after the start of
the DOCA-salt treatment, systolic blood pressure was signiﬁcantly
increased and remained higher until the sixth week of the treat-
ment, as shown in Fig. 4A. We have previously shown that after
4 weeks of DOCA-salt, rats presented increased cardiac ejection
M.F. Dias-Peixoto et al. / Peptides 35 (2012) 196–201 199
Fig. 2. Effects of swimming training on Mas  expression in hearts. (A) Swim train-
ing  induced signiﬁcant left ventricular (p = 0.01) and (B) cardiomyocyte (p < 0.001)
hypertrophy. (C) Representative western blot and (D) quantiﬁcation of Mas in hearts
of  untrained and trained rats. Mas  protein levels were not altered in swim-trained
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Fig. 3. Effects of isoproterenol on Mas  expression in hearts. (A) Isoproterenol
treatment induced a signiﬁcant left ventricular hypertrophy (p = 0.005) and (B)
cardiomyocyte hypertrophy (p = 0.034). (C) Representative western blot and (D)
quantiﬁcation of Mas  in hearts of vehicle- and isoproterenol-treated rats (p = 0.002).ats (p = 0.59). GAPDH expression levels were used as a loading control. *p < 0.05 vs.
ntrained rats (Student t-test. a.u. = arbitrary units).
raction when compared to SD control rats [21]. We  now extend this
nding and show that after 6 weeks of treatment cardiac ejection
raction is still higher in DOCA-salt rats when compared to con-
rols (Fig. 4B). Marked cardiac hypertrophy was observed at both
our and 6 weeks of DOCA-salt treatment (Fig. 4C and D). Impor-
antly, after 4 weeks of treatment western blot analysis revealed
imilar expression levels of Mas  between DOCA-salt and SD con-
rol rats (Fig. 4E), albeit at 6 weeks Mas  expression was signiﬁcantly
ncreased in left ventricles of DOCA-salt when compared to SD rats
Fig. 4F).
.5. Effects of myocardial infarction on Mas  expression in hearts
Additionally, we investigated changes in Mas expression in
earts at 7 and 21 days post-infarction. Fig. 5A and B shows that
ardiac expression of Mas  was not different between infarcted
nd sham-operated rats at 7 days. However, Mas  expression was
igniﬁcantly reduced after 21 days of myocardial ischemia when
ompared with hearts from sham-operated animals (Fig. 5C and
). Masson’s trichrome staining for collagen was used to conﬁrm
he presence of infarcted area (Supplementary Fig. 1).
. Discussion
The major ﬁnding of the present study is that Mas  expression in
he heart is regulated according to the stimulus which the animal
s submitted, and the stage of the disease. These stimuli include
ainly pathological challenges such as myocardial hypertrophy,
ypertension and infarction.GAPDH expression levels were used as a loading control. *p < 0.05 vs. vehicle-treated
rats (Student t-test. a.u. = arbitrary units).
Recent data have demonstrated that the RAS is composed by two
distinct axes, i.e. the hypertensive, hypertrophic and proliferative
axis formed by ACE, Ang II and AT1 receptor and the ACE2/Ang-(1-
7)/Mas branch, which has anti-hypertensive, anti-hypertrophic and
anti-proliferative actions [23]. Functionally, these two axes have
opposite effects, which help to maintain homeostasis of the car-
diovascular system. In the current study, we  demonstrated that
ACE2/Ang-(1-7)/Mas axis can be modulated at receptor level by
changing Mas  expression in response to different pathophysiolog-
ical conditions.
In this study, trained Wistar rats were used as a model of physi-
ological cardiac hypertrophy while isoproterenol-treated rats were
considered a model of pathological cardiac hypertrophy. The car-
diac hypertrophy and the increased time to exhaustion observed
in trained Wistar rats indicated that the swimming training pro-
tocol used in this study was  physiologically efﬁcient. In spite of
this and in agreement with our previous study [9],  we did not
observe signiﬁcant changes in Mas  expression in the left ventri-
cle of trained normotensive rats. Although the swimming training
protocol used here was  quite different from the protocol used in
our previous study both ﬁndings support the notion that physical
training alters Mas  cardiac expression mainly in diseased states.
In fact, Mas  expression was increased only in hearts of SHR [9].
Nevertheless, we cannot discard the possibility that the absence
of changes in Mas  expression in hearts of normotensive rats in
response to physical training may  be related to the intensity and/or
duration of the exercise protocol. Interestingly, if we compare the
cardiac mass index of the isoproterenol-injected animals with the
200 M.F. Dias-Peixoto et al. / Peptides 35 (2012) 196–201
Fig. 4. Effects of DOCA treatment on cardiac Mas  expression. (A) Systolic blood pres-
sure was  measured every week during 6 weeks of treatment. *p < 0.05 vs. control
rats (two-way ANOVA followed by the Bonferroni post test). (B) Echocardiographic
analysis showed a signiﬁcant increase in ejection fraction after 6 weeks of DOCA-
salt  treatment. (C–D) Cardiac hypertrophy was observed at 4 and 6 weeks after the
beginning of DOCA-salt treatment. Representative western blot and quantiﬁcation
of  Mas in hearts of control and DOCA-salt rats after 4 (E) and 6 (F) weeks of treat-
ment. Signiﬁcant increase in Mas  expression was  observed only in the DOCA-salt
group after 6 weeks of treatment (p = 0.034). GAPDH expression levels were used
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Fig. 5. Effects of infarction on Mas  expression in hearts. (A) Representative western
blot  and (B) quantiﬁcation of Mas  in hearts of sham and infarcted rats after 7 days
of infarction. Mas  protein levels were not altered in infarcted rats (p = 0.553). (C)
Representative western blot and (D) quantiﬁcation of Mas in hearts of sham ands  a loading control. *p < 0.05 vs. vehicle-treated rats (Student t-test. a.u. = arbitrary
nits).
ndex of the physical-trained rats, the hypertrophy induced by the
ormer was higher than the one induced by swimming training.
his distinction may  also explain the differential modulation of
as  expression observed under these two conditions. Therefore,
t is possible that a higher duration and/or intensity of training
xercise may  lead to a more marked cardiac hypertrophy and pos-
ible changes in cardiac Mas  expression. Moreover, it should be
oted that the signaling pathways activated during the develop-
ent of physiological hypertrophy induced by physical training
re quite different from those activated by pathological stimuli.
long this line, another important point to consider is the evalua-
ion of the cardiac structure. Cardiomyocyte loss with subsequent
ypertrophy of the remaining cells is a common alteration found
n pathological hypertrophy [7].  In contrast, physical training is
enerally followed by beneﬁcial cardiomyocyte hypertrophy and
eduction in the deposition of ﬁbrotic tissue [19]. We  speculate that
 distinct expression pattern of Mas  in cardiomyocytes and cardiac
broblasts might explain, at least in part, why physical training did
ot change the expression of Mas  whereas chronic treatment with
soproterenol induced a reduction in cardiac Mas  expression.
Next, we used DOCA-salt hypertensive rats and infarcted rats in
hich cardiac Mas  expression was assessed at two  different time
rames. DOCA-salt rats presented a signiﬁcant increase in cardiac
unction and cardiac hypertrophy after 4 and 6 weeks of treatmentinfarcted rats after 21 days of infarction (p = 0.004). GAPDH expression levels were
used as a loading control. *p < 0.05 vs. sham rats (Student t-test. a.u. = arbitrary units).
when compared to control rats. However, cardiac Mas  expression
in DOCA-salt rats was  different from control rats only after 6 weeks
of treatment. This result is especially important as it shows that
changes in cardiac function or structure are not always accom-
panied by changes in Mas  expression levels. Nevertheless, it is
plausible that Mas  expression could decrease in DOCA rats with
the progression of the disease. In fact, at the time frame investi-
gated in this study DOCA rats were hypertensive with compensated
cardiac function, as shown by echocardiography measurements. In
this way, evaluation of Mas  expression at additional time-points is
important in order to further understand the relationship between
disease progression and expression of Mas  in different experimen-
tal models. Since higher or lower levels of Mas  expression do not
necessarily represent gain or loss of receptor functional activity,
it is of fundamental importance to assess in future studies Mas
functionality, as well as expression levels of ACE2 and Ang-(1-7).
Finally, we assessed cardiac Mas  expression at 7 and 21 days
post-infarction. Interestingly, at the early stage (7 days) cardiac Mas
expression did not change when compared to sham group. How-
ever, at a later stage (21 days) cardiac Mas  expression decreased
signiﬁcantly. In keeping with this ﬁnding, Ocaranza et al. [15] have
shown that cardiac ACE2 activity decreases with the progression of
cardiac disease. Importantly, in this study the authors have demon-
strated that cardiac ACE2 activity increases after 1 week of cardiac
infarction in rats, while at 8 weeks post injury infarcted rats pre-
sented a signiﬁcant decrease in ACE2 activity when compared to
control rats. Thus, these results suggest that ACE2/Ang-(1-7) is
generally elevated at the beginning of the establishment of the
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ardiovascular disease, possibly as an attempt of limiting the dam-
ge, while it is depressed in the late phase of disease. In agreement,
ur study shows that Mas  expression levels were altered mainly at
 later stage. One possibility is that changes in Mas  expression could
e a consequence of risk factors and/or events involved in heart dys-
unction or diseases, such as pro-inﬂammatory factors or oxidative
tress. In fact, it has been proposed that Ang-(1-7)/Mas counter reg-
lates the pro-inﬂammatory and increased oxidative stress induced
y Ang II/AT1 receptor [17]. Therefore, it is possible that pro-
nﬂammatory cytokines and increased oxidative stress, commonly
ound in disease states, may  inﬂuence cardiac Mas  expression. It is
mportant to note that, in our present study, we cannot rule out the
ossibility that different rat strains (Wistar vs. Sprague-Dawley)
nﬂuenced our results since distinct rat strains can respond dif-
erently to injury and physical training. Anyway, a different Mas
xpression pattern was observed in response to various patholog-
cal insults with Mas  found to be up or down-regulated.
. Conclusion
Our present study demonstrated that the expression of Mas  is
esponsive to different pathophysiological stimuli. These ﬁndings
orroborate the premise that Mas  is involved in the homeostasis of
he heart and disturbances in its expression may  contribute to the
stablishment and progression of cardiac diseases.
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